ALTIMMUNE INC (ALT) Fundamental Analysis & Valuation
NASDAQ:ALT • US02155H2004
Current stock price
3.53 USD
-0.09 (-2.49%)
At close:
3.54 USD
+0.01 (+0.28%)
After Hours:
This ALT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ALT Profitability Analysis
1.1 Basic Checks
- ALT had negative earnings in the past year.
- In the past year ALT has reported a negative cash flow from operations.
- In the past 5 years ALT always reported negative net income.
- In the past 5 years ALT always reported negative operating cash flow.
1.2 Ratios
- ALT has a Return On Assets of -31.47%. This is in the better half of the industry: ALT outperforms 64.86% of its industry peers.
- ALT's Return On Equity of -39.17% is fine compared to the rest of the industry. ALT outperforms 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.47% | ||
| ROE | -39.17% | ||
| ROIC | N/A |
ROA(3y)-47.23%
ROA(5y)-45.4%
ROE(3y)-53.9%
ROE(5y)-51.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ALT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ALT Health Analysis
2.1 Basic Checks
- ALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ALT has more shares outstanding than it did 1 year ago.
- ALT has more shares outstanding than it did 5 years ago.
- ALT has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.22, we must say that ALT is in the distress zone and has some risk of bankruptcy.
- ALT has a better Altman-Z score (1.22) than 62.55% of its industry peers.
- A Debt/Equity ratio of 0.15 indicates that ALT is not too dependend on debt financing.
- The Debt to Equity ratio of ALT (0.15) is worse than 64.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.22 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
- ALT has a Current Ratio of 18.55. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
- ALT has a better Current ratio (18.55) than 94.98% of its industry peers.
- ALT has a Quick Ratio of 18.55. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
- ALT has a Quick ratio of 18.55. This is amongst the best in the industry. ALT outperforms 94.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.55 | ||
| Quick Ratio | 18.55 |
3. ALT Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 24.63% over the past year.
- Looking at the last year, ALT shows a very strong growth in Revenue. The Revenue has grown by 105.00%.
- The Revenue for ALT have been decreasing by -65.33% on average. This is quite bad
EPS 1Y (TTM)24.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)105%
Revenue growth 3YN/A
Revenue growth 5Y-65.33%
Sales Q2Q%420%
3.2 Future
- Based on estimates for the next years, ALT will show a very strong growth in Earnings Per Share. The EPS will grow by 51.66% on average per year.
- The Revenue is expected to grow by 824.40% on average over the next years. This is a very strong growth
EPS Next Y-23.08%
EPS Next 2Y-4.96%
EPS Next 3Y70.96%
EPS Next 5Y51.66%
Revenue Next Year-58.8%
Revenue Next 2Y5482.76%
Revenue Next 3Y2942.88%
Revenue Next 5Y824.4%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. ALT Valuation Analysis
4.1 Price/Earnings Ratio
- ALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ALT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ALT's earnings are expected to grow with 70.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.96%
EPS Next 3Y70.96%
5. ALT Dividend Analysis
5.1 Amount
- No dividends for ALT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ALT Fundamentals: All Metrics, Ratios and Statistics
3.53
-0.09 (-2.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2026-03-05/bmo
Earnings (Next)05-11 2026-05-11/bmo
Inst Owners49.01%
Inst Owner Change21.03%
Ins Owners0.7%
Ins Owner Change3.92%
Market Cap398.29M
Revenue(TTM)41.00K
Net Income(TTM)-88.09M
Analysts78.67
Price Target18.67 (428.9%)
Short Float %22.77%
Short Ratio5.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.99%
Min EPS beat(2)-10.16%
Max EPS beat(2)26.14%
EPS beat(4)3
Avg EPS beat(4)15.58%
Min EPS beat(4)-10.16%
Max EPS beat(4)29.11%
EPS beat(8)6
Avg EPS beat(8)9.96%
EPS beat(12)10
Avg EPS beat(12)13.55%
EPS beat(16)14
Avg EPS beat(16)13.85%
Revenue beat(2)2
Avg Revenue beat(2)1910.88%
Min Revenue beat(2)296.04%
Max Revenue beat(2)3525.71%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.38%
EPS NQ rev (1m)5.6%
EPS NQ rev (3m)8.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.86%
Revenue NQ rev (1m)-29%
Revenue NQ rev (3m)-29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9714.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.77 | ||
| P/tB | 1.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.01
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.47% | ||
| ROE | -39.17% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-47.23%
ROA(5y)-45.4%
ROE(3y)-53.9%
ROE(5y)-51.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.82% | ||
| Cap/Sales | 26.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.55 | ||
| Quick Ratio | 18.55 | ||
| Altman-Z | 1.22 |
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-23.08%
EPS Next 2Y-4.96%
EPS Next 3Y70.96%
EPS Next 5Y51.66%
Revenue 1Y (TTM)105%
Revenue growth 3YN/A
Revenue growth 5Y-65.33%
Sales Q2Q%420%
Revenue Next Year-58.8%
Revenue Next 2Y5482.76%
Revenue Next 3Y2942.88%
Revenue Next 5Y824.4%
EBIT growth 1Y8.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.11%
EBIT Next 3Y4.13%
EBIT Next 5Y26.2%
FCF growth 1Y15.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.42%
OCF growth 3YN/A
OCF growth 5YN/A
ALTIMMUNE INC / ALT Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ALTIMMUNE INC (ALT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ALT.
What is the valuation status for ALT stock?
ChartMill assigns a valuation rating of 1 / 10 to ALTIMMUNE INC (ALT). This can be considered as Overvalued.
Can you provide the profitability details for ALTIMMUNE INC?
ALTIMMUNE INC (ALT) has a profitability rating of 1 / 10.
How financially healthy is ALTIMMUNE INC?
The financial health rating of ALTIMMUNE INC (ALT) is 4 / 10.